Compare COEP & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COEP | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 31.9M |
| IPO Year | N/A | 2012 |
| Metric | COEP | VNRX |
|---|---|---|
| Price | $11.70 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 41.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $60.84 |
| Revenue Next Year | N/A | $404.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $6.32 | $0.17 |
| 52 Week High | $21.41 | $0.94 |
| Indicator | COEP | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 38.77 |
| Support Level | $10.74 | N/A |
| Resistance Level | $12.71 | $0.33 |
| Average True Range (ATR) | 0.74 | 0.03 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 35.87 | 28.48 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.